The strongest version of this narrative highlights a genuine medical dilemma: osteoarthritis pain is poorly managed by current treatments, and anti-NGF therapies offered unprecedented relief but were derailed by legitimate safety concerns. The source deserves credit for presenting the scientific progress, regulatory challenges, and ongoing research without oversimplifying the trade-offs. However, the pattern of framing this as a "lost opportunity" without deeper interrogation of the regulatory p...